Studies have shown that consuming sesame seeds helps prevent allergies.

Published Date: 06 Mar 2023

Oral desensitization using crushed sesame seeds and tahini may be a safe and effective method to desensitize pediatric patients with sesame allergy...

Read Full News

Latest News

FDA Approves First Oral Drug for Dermatomyositis in Adults

The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune disease, in adults.

Early Step-Down Safe, Cost-Effective in Stable Candidiasis

Switching from an echinocandin to an azole within 5 days is not associated with worse outcomes in clinically stable adults with invasive candidiasis, a study shows.

How Safe Is Lifileucel After Patients Go Home?

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

China Approves J&J Psoriasis Pill Icotyde, Says Drugmaker

China's drug regulator has approved Johnson & Johnson's oral pill ⁠for psoriasis, the company said on Thursday, intensifying competition in the ⁠world's second-largest...

Vulvar Lichen Sclerosus Affects 1 in 700 US Women

Vulvar lichen sclerosus shows markedly higher rates in women over 60, with White women experiencing the highest burden, a study shows.

Brepocitinib Controls Skin Disease in Dermatomyositis

Brepocitinib produces rapid and sustained improvements in skin disease, itch, and skin-related quality of life in adults with dermatomyositis.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune disease, in adults.

Switching from an echinocandin to an azole within 5 days is not associated with worse outcomes in clinically stable adults with invasive candidiasis, a study shows.

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

China's drug regulator has approved Johnson & Johnson's oral pill ⁠for psoriasis, the company said on Thursday, intensifying competition in the ⁠world's second-largest...

Vulvar lichen sclerosus shows markedly higher rates in women over 60, with White women experiencing the highest burden, a study shows.

Brepocitinib produces rapid and sustained improvements in skin disease, itch, and skin-related quality of life in adults with dermatomyositis.

News All Time

FDA Staff Unconvinced Drug for Melanoma Shows Benefit

Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting

Fauci's Diaries Released; Cold Brew Recalled; Carly Simon's Diagnosis

Health news and commentary gathered by MedPage Today staff

What Is the 'Barbie Peptide' and Why Is It Risky?

Dermatologists weigh in on the injectable trend

Twice-Rejected Melanoma Drug Gets Love From FDA Panel

Vote at odds with FDA reviewers

Make the Diagnosis: She’s Losing Her Scalp and Eyebrow Hair. Why?

A 51-year-old woman visited her doctor for asymptomatic hair loss on her scalp and eyebrows that she first noticed approximately 5 months prior. Can you diagnose the patient?

FDA Finally OKs Twice-Rejected Melanoma Drug

Approved in combination with nivolumab for patients who progress on prior anti-PD-1 therapy

'Carrot Maxxing' Is a New Name for an Old Trend

Eating lots of carrots can change the color of the skin, but satisfaction may vary

Tanning Is Getting Hot Again. Here's What It Really Does to Your Skin.

Tanning misinformation abounds online

Pebbled Skin and Excessive Hair Growth on a 5-Year-Old's Back

Just two of the multiple symptoms that began to emerge shortly after birth

Can 'Ferritin Face' Signal Underlying Anemia? Hematologists Weigh In

Patients attribute dull skin, brittle hair, and dark under-eye circles to ferritin deficiency

JAK Inhibitor Might Be the Most Effective One Yet for Severe Alopecia

Trials suggest more hair growth with upadacitinib in teens and adults than previously seen

Flight Attendants, Pilots Have Highest Risk of Dying From Radiation-Linked Cancers

Radiation exposure is greater for people flying at high altitudes

4 Deaths Linked to Medical Device; New FDA Chief? Human-Chimp Hybrid Attempt

Health news and commentary gathered by MedPage Today staff

How Much of a Cancer Drug Is Too Much? Some Are Challenging FDA-Approved Dosages.

— Smaller doses of some drugs could save billions and prevent some of the worst side effects

US FDA Approves Regeneron's Rare Bone Disorder Drug

Aug 19 - The U.S. FDA on Wednesday approved Regeneron's drug for a rare genetic disorder ⁠after it significantly reduced abnormal bone formation in certain soft...

Ebola Spreading Exponentially in Congo as Death Toll Tops 2,500, UN Says

More than 2,500 people have now died in the Democratic Republic of Congo's Ebola outbreak, which is spreading exponentially in an area larger ⁠than France, senior United...

Recommended News For You

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

Novel Psychedelic Promising on Resistant Depression

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

New imaging guidelines for head and neck cancers, a step toward practice change

Recommended Articles For You

How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care? 

Hypogammaglobulinemia: A Comprehensive Guide for Patients and Caregivers 

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape 

Neonatal Hematopoietic Transition and Blood Cell Maturation 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Independent Risk Factors for "Deaths of Despair" Found.

2.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

3.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

4.

Infection Burden High With Myeloma T-Cell Therapies

5.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

1.

Genomic Control of Erythropoietic Stem Cell Renewal

2.

Case-Based Learning on Unexpected Cytopenia Patterns Following Advanced Therapies

3.

Subchorionic Hematoma: Causes, Symptoms, and Treatment 

4.

Clonal Hematopoiesis as a Mechanism of Age-Related Disease

5.

Transformative Insights in Oncology in Daily Practice

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Innovations in Hematology

2.

Case-Based Learning: Oncology

3.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

4.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion

5.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot